ArriVent BioPharma (AVBP) Competitors $20.89 -0.88 (-4.04%) Closing price 04:00 PM EasternExtended Trading$19.80 -1.09 (-5.22%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. KYMR, MTSR, CRNX, VKTX, MLTX, MOR, ALVO, HCM, IMVT, and CPRXShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Kymera Therapeutics (KYMR), Metsera (MTSR), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Alvotech (ALVO), HUTCHMED (HCM), Immunovant (IMVT), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Its Competitors Kymera Therapeutics Metsera Crinetics Pharmaceuticals Viking Therapeutics MoonLake Immunotherapeutics MorphoSys Alvotech HUTCHMED Immunovant Catalyst Pharmaceuticals ArriVent BioPharma (NASDAQ:AVBP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Is AVBP or KYMR more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -409.07%. Kymera Therapeutics' return on equity of -30.11% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -49.21% -46.61% Kymera Therapeutics -409.07%-30.11%-25.65% Which has better earnings and valuation, AVBP or KYMR? ArriVent BioPharma has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$80.49M-$3.77-5.54Kymera Therapeutics$47.07M61.48-$223.86M-$3.10-14.34 Which has more volatility and risk, AVBP or KYMR? ArriVent BioPharma has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Do analysts prefer AVBP or KYMR? ArriVent BioPharma currently has a consensus price target of $40.00, suggesting a potential upside of 91.48%. Kymera Therapeutics has a consensus price target of $59.61, suggesting a potential upside of 34.14%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe ArriVent BioPharma is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer AVBP or KYMR? In the previous week, Kymera Therapeutics had 14 more articles in the media than ArriVent BioPharma. MarketBeat recorded 35 mentions for Kymera Therapeutics and 21 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.50 beat Kymera Therapeutics' score of 0.37 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of AVBP or KYMR? 9.5% of ArriVent BioPharma shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArriVent BioPharma beats Kymera Therapeutics on 8 of the 15 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$714.65M$2.87B$5.52B$8.86BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-5.5421.1926.3919.77Price / SalesN/A264.39408.83110.45Price / CashN/A41.2925.8827.49Price / Book2.737.237.915.36Net Income-$80.49M-$55.05M$3.15B$248.34M7 Day Performance-9.61%-0.58%1.04%1.28%1 Month Performance-1.46%6.50%5.36%5.45%1 Year Performance15.10%0.22%32.71%18.02% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.7826 of 5 stars$20.89-4.0%$40.00+91.5%+17.4%$714.65MN/A-5.5440KYMRKymera Therapeutics3.0974 of 5 stars$47.30+2.2%$59.82+26.5%+46.2%$3.09B$58.89M-15.30170Trending NewsInsider TradeAnalyst RevisionGap UpMTSRMetseraN/A$28.52-1.7%$55.00+92.8%N/A$3.00BN/A0.0081Gap DownCRNXCrinetics Pharmaceuticals3.5599 of 5 stars$31.17+4.2%$74.56+139.2%-35.8%$2.92B$1.04M-8.17210VKTXViking Therapeutics4.1556 of 5 stars$25.72+3.5%$87.15+238.9%-50.0%$2.90BN/A-22.4620MLTXMoonLake Immunotherapeutics2.2755 of 5 stars$45.31+1.0%$78.71+73.7%+7.3%$2.90BN/A-19.702MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech3.7281 of 5 stars$9.22+1.0%$18.00+95.3%-25.0%$2.79B$491.98M24.991,032HCMHUTCHMED1.7955 of 5 stars$15.83+4.1%$19.00+20.0%-12.1%$2.76B$630.20M0.001,811Positive NewsIMVTImmunovant1.9629 of 5 stars$15.84+2.4%$38.33+142.0%-39.4%$2.72BN/A-5.81120CPRXCatalyst Pharmaceuticals4.9302 of 5 stars$22.05-0.3%$32.83+48.9%+40.1%$2.70B$491.73M14.1180Positive News Related Companies and Tools Related Companies Kymera Therapeutics Competitors Metsera Competitors Crinetics Pharmaceuticals Competitors Viking Therapeutics Competitors MoonLake Immunotherapeutics Competitors MorphoSys Competitors Alvotech Competitors HUTCHMED Competitors Immunovant Competitors Catalyst Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
